benmelciclib + irinotecan

Benmelciclib + irinotecan is a combination therapy consisting of benmelciclib (TQB3616), an orally bioavailable selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), and irinotecan, a topoisomerase I inhibitor. Benmelciclib works by blocking the transition from the G1 to the S phase of the cell cycle, thereby inhibiting tumor cell proliferation. Irinotecan, a derivative of camptothecin, induces double-strand DNA breaks by stabilizing the topoisomerase I-DNA complex. This combination is primarily being investigated by Chia Tai Tianqing Pharmaceutical Group for the treatment of advanced solid tumors, including colorectal cancer and small cell lung cancer, where CDK4/6 inhibition may enhance the cytotoxic effects of chemotherapy or overcome resistance.

Other names

TQB3616 + irinotecanbenmelciclib + irinotecan hydrochloride